Amonafide

Amonafide
Clinical data
Trade names	Xanafide, Quinamed
ATC code	none;
Identifiers
	IUPAC name 5-amino-2-[2-(dimethylamino)ethyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione;
CAS Number	69408-81-7;
PubChem CID	50515;
ChemSpider	45804 ;
UNII	1Q8D39N37L;
KEGG	D10090 ;
ChEMBL	ChEMBL428676 ;
CompTox Dashboard (EPA)	DTXSID30219562 ;
Chemical and physical data
Formula	C16H17N3O3
Molar mass	283.325 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C2c1c3c(ccc1)cc(cc3C(=O)N2CCN(C)C)N;
	InChI InChI=1S/C16H17N3O2/c1-18(2)6-7-19-15(20)12-5-3-4-10-8-11(17)9-13(14(10)12)16(19)21/h3-5,8-9H,6-7,17H2,1-2H3 ; Key:UPALIKSFLSVKIS-UHFFFAOYSA-N ;
(verify)

Amonafide (originally AS1413) (INN, trade names Quinamed and Xanafide) is a drug that is being studied in the treatment of cancer. It belongs to a novel family of chemotherapeutic drugs called Naphthalimides and is a potential topoisomerase inhibitor and DNA intercalator.

It is being developed as an anti-cancer therapy by Antisoma.[1]

As of 2008, it is in Phase III clinical trials. e.g. In March 2010 it is Phase III trial against secondary acute myeloid leukaemia (AML).[2] In June 2010, it gained an FDA Fast Track Status for the treatment of Secondary Acute Myeloid Leukaemia.

References

http://www.genengnews.com/news/bnitem.aspx?name=78979622
http://clinicaltrials.gov/ct2/show/NCT00715637 "Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study"

External links

Amonafide entry in the public domain NCI Dictionary of Cancer Terms
Clinical trials of amonafide at ClinicalTrials.gov

This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] ttp://www.genengnews.com/news/bnitem.aspx?name=78979622

[2] ttp://clinicaltrials.gov/ct2/show/NCT00715637 "Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study"

Amonafide

See also

References

External links